This dovetails nicely with ongoing work suggesting DUSP6 contributes to JAK2 inhibitor resistance and may be a therapeutic target in myelofibrosis [97], an unexpected finding given DUSP6 inhibition would in theory enhance ERK activity. Here, JAK2 is linked to myelofibrosis.